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Years of study 
Aim  
Study design 
Population Intervention Outcomes reported 
Korones et al 
(2001)7 
USA 




To determine the frequency of 
detection of recurrent / 
progressive brain tumors in 
asymptomatic children are 
detected by surveillance MRI 
scans and to compare the survival 
of children with asymptomatic 
recurrence compared to those 
whose recurrences are detected by 
symptoms  
Retrospective case series study 
 
Included: Patients with a brain tumor aged < 
21 at diagnosis and for which neuro-imaging 
surveillance was performed exclusively by 
MRI.  
Excluded: Patients with spinal cord tumors 
or children followed by CT scans. 
Tumor type: both low and high-grade 
tumors, including 33 (72%) recurrent high-
grade tumors including:  
‐ HGG (anaplastic astrocytoma, 
glioblastoma multiforme): n=10 (30%) 
‐ Brainstem glioma: n=7 (21%) 
‐ sPNET: n=5 (16%) 
‐ MB: n=4 (12%) 
‐ Epend: n=4 (12%) 
‐ CPC: n=1 (3%) 
‐ GCT: n=1 (3%) 
‐ AT/RT: n=1 (3%) 
 
N = 112 (although paper focuses exclusively 
on the 46 recurrent patients) 
Male: 45% 
Median age at diagnosis (n=46):  
6.5 years (0.25 – 21) 
Median age at recurrence for 33 high grade 
patients: 6 years (0.25 – 21) 
Average follow-up: NR 
Tumor location: NR 
Previous treatment(s): 
‐ Surgery: n = NR 
Surveillance MRI. 
Details:  
 MRI scanner: No details.  
 Image sequences taken: No 
details 
 Imaging schedule: 
1 scan every 2.5 mths 
(range 1/1 mth to 1/ 6.7 
mths). 
 Average number of MRI 
images per patient: 
NR for high-grade tumor 
patients only 
 
Surveillance MRI: “Scans 
done ≥1 month after surgery 
(or >1 month after the original 
diagnostic MRI if diagnosis 
was by MRI only) were 
considered surveillance scans.  
Immediate post-operative 





 Recurrence by symptomatic status 
 Median time from diagnosis to 
recurrence by tumor grade 
 Median OS by symptomatic status 
for all patients 
 Median OS for symptomatic status 
for high grade tumor patients 
 Overall survival (n=46) 
 2-year OS from time of recurrence 
by symptomatic status 
 
Kornreich et al 
(2005)8 
Israel 
1985 - 2001 
 
To describe the MR findings of 
pontine tumors at diagnosis and 
during follow-up and correlate 
those with prognosis and to assess 
the value of MR imaging in 
Included: Patients with a DIPG “according 
to the classification of Barkovich et al 
(center of the mass in the pons, involving 
>50% of the axial area) who underwent MR 
imaging at diagnosis and at least once during 
Surveillance MRI 
Details:  
 MRI scanner: no details. 
 Image sequences taken: All 
patients underwent at least 
 Progression rate 
 Medium time to progression 
 Median OS 




Years of study 
Aim  
Study design 
Population Intervention Outcomes reported 
 patient management compared 
with clinical evaluation. 
Retrospective case series study 
treatment.” 
Excluded: NR 
Tumor grade: only pathologically 
confirmable in the 3 patients who underwent 
surgery at diagnosis:   
‐ glioblastoma multiforme (n=1) 
‐ astrocytoma grade II (n=1) 
‐ astrocytoma grade III (n=1) 
 
Tumor location: “center of the mass in the 
pons, involving >50% of the axial area” 
 
N = 15 
Male: 73% 
Median age at diagnosis: 5.6 years (range 
 2–19) 
Average follow-up:  
‐ Median: 1.5 yearsa (range 0.17 to 9) 
‐ Mean: 2.17 years 
Previous treatment(s):- 
- Surgery (n=3 patients with a posterior 
cystic exophytic component underwent 
surgery at diagnosis) 
T1-weighted (T1W) sagittal 
and T1W and T2W axial 
sequences, with contrast 
agent (gadopentate 




 Tumor response rates 
 Changes in patient treatment due to 
progression 
 
Perreault et al 
(2014)9 
USA 




To assess the benefits of 
surveillance MRI and more 
specifically spine MRI in a 
contemporary cohort. 
Retrospective case series study 
Included: Patients “with at least one 
surveillance MRI following the diagnosis of 
MB, ATRT, PB, (s)PNET, (s)HGG (World 
Health Organization grade III–IV), CNS 
GCT or Epend.” 
Excluded: Patients with “a malignant CNS 
tumor involving only the spine at diagnosis”. 
N = 258 
Male: 62% 
Median age at diagnosis: 8 years (range 0.3 
– 21) 
Median follow-up (n=258): 3.12 years 




 No details of the MRI 





 Median follow-up; total and by 
tumor type 
 Median number of scans (range); 
total and by tumor type 
 Recurrence rate; total and by tumor 
type: first and subsequent 
recurrences 
 Symptomatic status at recurrence 
 Median time to recurrence; total 
and by tumor type; by symptomatic 
status at recurrence. 





Years of study 
Aim  
Study design 
Population Intervention Outcomes reported 
 
Tumor type(s): Mixed: 
‐ MB: n=89 (35%) 
‐ AT/RT: n=10 (4%) 
‐ PB: n=9 (3%) 
‐ sPNET: n=25 (10%) 
‐ HGG: n=34 (13%) 
‐ GCT: n=39 (15%) 
‐ Ependymoma: n=52 (20%) 
Tumor grade:  
‐ HGG: WHO grade III–IV 
‐ GCT: WHO II and III 
‐ Epend: WHO II and III 
Tumor location: supratentorial (reported for  
PNET and HGG only) 
Previous treatment(s): NR 
 
 Frequency of MRI-detected 
recurrence; total and by tumor type 
 Changes in patient treatment due to 
recurrence after first relapse 
 
Key: AT/RT: Atypical Teratoid/Rhabdoid Tumor; CPC: Choroid Plexus Carcinoma; DIPG: Diffuse Pontine Glioma; Epend: Ependymoma; GCT: Germ Cell tumor;  
HGG: High Grade Glioma; MB: Medulloblastoma; MRI: Magnetic Resonance Imaging; mth(s): month(s); PB: Pineoblastoma; N: number of patients; N/A: not applicable; ND: not 
defined; NR: not reported; (s)HGG: (supratentorial) High Grade Glioma; (s)PNET: (supratentorial) Primitive Neuroectodermal Tumor; WHO: World Health Organization 
aNot directly reported by the authors but calculated by the reviewer based on data reported in the publication.  














recurrent disease  
n (%) 
Diagnostic 







Median time to recurrence  
in years (range) 
Asymp Symp Asymp Symp 
Total 33 1 scan / 2.5  (1/1 – 1/6.7) 17 (52) 16 (48) 4.4 (656 scans) 
0.75  
(0.17 – 6) 
0.75 
(0.17 – 4.33) 
0.67 
(0.17 – 6) 
HGG 10 NR 4 (40) 6 (60) 6.3 (63 scans) NR NR NR 
DIPG 7 NR 3 (43) 4 (57) 15.3 (19 scans) NR NR NR 
sPNETa 5 NR 3 (60) 2 (40) 7.2 (42 scans) NR NR NR 
MB 4 NR 2 (50) 2 (50) 1.4 (147 scans) NR NR NR 
Epend 4 NR 3 (75) 1 (25) 3.5 (86 scans) NR NR NR 












































Total  258  3.13  13  52 (46)  47 (42)  14 (12)  36 (29)  58 (46)  31 (25)  8.3  3.8  0.9  1.0 (0.03–11.4)  2.83 
MB  89  4.33  18.5  17 (63)  6 (22)  4 (15)  6 (21)  12 (41)  11 (38)  5.2  2.5  0.7  1.3 (0.04–6.3)  2.17 
Epend  52  3.96  11  12 (46)  7 (27)  7 (27)  10 (26)  15 (38)  14 (36)  11.3  4.3  1.1  1.3 (0.08–5.4)  3.0 
GCT  39  4.25  15  5 (56)  4 (44)  0 (0)  1 (50)  1 (50)  0 (0)  2.1  2.4  1.6  3.17 (0.08–11.4)  8.1 
HGG  34  1.25  6  7 (25)  19 (68)  2 (7)  5 (19)  19 (73)  2 (8)  21.6  11.4  2.8  0.88 (0.07‐3.17)  2.25 
sPNETa  25  3.75  17  5 (36)  8 (57)  1 (7)  11 (58)  6 (32)  2 (10)  10.5  1.6  0  0.96 (0.03‐4.5)  2.42 
AT/RT  10  0.54  7  4 (100)  0 (0)  0 (0)  2 (67)  1 (33)  0 (0)  10.9  13  0  0.46 (0.42‐0.75)  0.75 
PB  9  2.08  16  2 (40)  3 (60)  0 (0)  1 (14)  4 (57)  2(29)  9.3  19.7  4.9  1.67 (0.92‐2.5)  2.5 
 
Key: Asymp, asymptomatic; AT/RT, Atypical Teratoid / Rhabdoid Tumor; B, brain only; B/S, combined brain and spine; Epend, Ependymoma; GCT, Germ Cell Tumor; HGG, High Grade Glioma; 
MB, Medulloblastoma; N, number of patients; PB, Pineoblastoma; sPNET, supratentorial Primitive Neuroectodermal Tumor; s, spine only; symp, symptomatic. 
aAs of 2016, the term PNET no longer appears in the current WHO classification of CNS tumors 
 
